AI Eye-Screening Firm Wins Prix Galien Award

AEYE Health received the 2026 Prix Galien USA Award for Best Digital Health Solution for AEYE-DS, its fully autonomous artificial intelligence tool for detecting diabetic eye disease. The Israeli-American digital health company says the system could make screening available at more points of care. The award recognizes a product. It doesn’t, by itself, tell patients how widely the technology is available or what an examination costs.

The Promise of Easier Screening

Diabetic retinopathy damages blood vessels in the retina, at the back of the eye, and can develop as a complication of diabetes. According to the base report, it’s the leading cause of blindness among working-age adults. Early on, it may cause no symptoms or only mild visual disturbances. Left untreated, it can lead to blindness. Early detection and intervention can prevent most vision loss from the condition.

AEYE Health says conventional screening by an eye specialist can be difficult to access. The company cites limited availability, long waits, cost and inconvenience as barriers that may delay detection and lead to vision loss. AEYE-DS aims to address those access problems. The account gives no figures for how many people currently use the technology, what screening costs, or how many patients have received care through it.

The system works with portable and tabletop retinal cameras. Its FDA-cleared diagnostic program uses AI to conduct diabetic eye examinations and returns results almost immediately, the report says, without requiring a physician’s interpretation. That’s the company’s claim: the setup can bring an examination to virtually any point of care. The award announcement doesn’t establish whether that promise translates into access for patients facing cost or availability barriers.

Award, Trials and Expansion

AEYE Health says it validated AEYE-DS through three prospective, controlled pivotal phase-III clinical trials and is rapidly expanding across the United States. The report doesn’t provide trial results, expansion details, or independent figures on accuracy or patient outcomes. Those distinctions matter. Intended use, regulatory clearance and reported clinical validation don’t show how many people the technology reaches or whose vision it preserves.

Dr. Zack Dvey-Aharon, Co-founder and CEO of AEYE Health, called the award “one of the greatest honors of my professional life and an extraordinary recognition of the work of the AEYE Health team.” He added, “our greatest achievement remains every patient whose sight can be preserved because this technology exists.” The statement describes the company’s ambition, but the announcement doesn’t quantify how many patients have had sight preserved because of AEYE-DS.

Dvey-Aharon also said, “We are only at the beginning of what autonomous AI can accomplish for global healthcare.” AEYE Health is developing AEYE-X, a next-generation platform intended to assess a wider range of health conditions from retinal images. The company says AEYE-X can assess more than 100 health indications, potentially extending retinal imaging beyond traditional eye care. The report provides no further detail about those indications or the platform’s clinical status. For now, the award recognizes AEYE-DS, while the company announcement leaves questions about cost, reach and measured patient benefit unanswered.